MolDX: Oncotype DX® Colon Cancer Assay Update

The Oncotype DX Colon Cancer Assay (CPT 81525) is intended to predict recurrence risk for patients with Stage II colon cancer. Billing requires CPT 81525, entering '1' in the Days/Unit field, submission of the appropriate DEX Z-Code adjacent to the CPT code in specified claim fields (SV101-7/SV202-7/NTE/Loop 2400/Box 19/Block 80), and selection of the appropriate ICD-10-CM diagnosis code.

"Oncotype DX Colon Cancer Assay is indicated to predict recurrence risk for patients with Stage II colon cancer."

Sign up to see full coverage criteria, indications, and limitations.